Agios Pharm Overview
Industry: Biotechnology
Sector: Healthcare
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; a Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Agios Pharm into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $20.7M (+138% YoY). Net loss was -$99.1M (from $89.3M). R&D expense was $81.1M.
What changed
- Revenue +138% YoY to $20.7M.
- Net loss was -$99.1M (from $89.3M).
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Headline from Yahoo Finance: Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release.
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
Headline from Zacks Investment Research: AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program.
H.C. Wainwright lowers Agios Pharma price target to $52 on trial data
Headline from Investing.com UK: H.C. Wainwright lowers Agios Pharma price target to $52 on trial data.
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
Headline from Yahoo Finance: AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program.
H.C. Wainwright lowers Agios Pharma price target to $52 on trial data By Investing.com
Headline from Investing.com South Africa: H.C. Wainwright lowers Agios Pharma price target to $52 on trial data By Investing.com.
Agios scraps sickle cell treatment after trial shows limited benefit
Headline from Reuters: Agios scraps sickle cell treatment after trial shows limited benefit.
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.